FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1374-1376 May 18, 1995 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Heparin-induced thrombocytopenia and associated thrombotic events, relatively common side effects of heparin therapy, can cause substantial morbidity and mortality. Typically, these conditions occur after about five days of therapy, but they can appear sooner in patients previously treated with heparin. Thrombocytopenia in itself rarely poses a threat to affected patients, but disorders associated with it, which include deep venous thrombosis, disseminated intravascular coagulation, pulmonary embolism, cerebral thrombosis, myocardial infarction, and ischemic injury to the legs or arms, can produce severe morbidity and mortality. In order to prevent these complications, it has become standard medical practice to monitor platelet counts in . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Shantsila, E., Lip, G. Y. H., Chong, B. H. (2009). Heparin-Induced Thrombocytopenia: A Contemporary Clinical Approach to Diagnosis and Management. Chest 135: 1651-1664 [Abstract] [Full Text]  
• Hutchison, C. A., Dasgupta, I. (2007). National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22: 1680-1684 [Abstract] [Full Text]  
• Warkentin, T. E., Cook, R. J., Marder, V. J., Sheppard, J.-A. I., Moore, J. C., Eriksson, B. I., Greinacher, A., Kelton, J. G. (2005). Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106: 3791-3796 [Abstract] [Full Text]  
• Sanfelippo, P. M. (2005). Heparin-Induced Thrombocytopenia--A Potential Iatrogenic Complication for Patients with Cardiac and Vascular Disease. ANGIOLOGY 56: 305-309 [Abstract]  
• Kumar, P., Hoppensteadt, D. A., Prechel, M. M., Deddish, R. B., Walenga, J. M. (2004). Prevalance of Heparin-Dependent Platelet-Activating Antibodies in Preterm Newborns After Exposure to Unfractionated Heparin. CLIN APPL THROMB HEMOST 10: 335-339 [Abstract]  
• Schenk, J. F., Pindur, G., Stephan, B., Mursdorf, S., Mertzlufft, F., Kroll, H., Wenzel, E., Seyfert, U. T. (2003). On the Prophylactic and Therapeutic Use of Danaparoid Sodium (Orgaran(R)) in Patients With Heparin-Induced Thrombocytopenia. CLIN APPL THROMB HEMOST 9: 25-32 [Abstract]  
• Young, S. K. (2002). New Treatment Options for Heparin-Induced Thrombocytopenia. Journal of Pharmacy Practice 15: 305-317 [Abstract]  
• Maloney, J. P. (2002). Lessening the Punch of Heparin-Induced Thrombocytopenia. Chest 122: 5-6 [Full Text]  
• Rosenthal, M. A., Rischin, D., McArthur, G., Ribbons, K., Chong, B., Fareed, J., Toner, G., Green, M. D., Basser, R. L. (2002). Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol 13: 770-776 [Abstract] [Full Text]  
• von Segesser, L. K, Mueller, X, Marty, B, Horisberger, J, Corno, A (2001). Alternatives to unfractioned heparin for anticoagulation in cardiopulmonary bypass. Perfusion 16: 411-416 [Abstract]  
• Ahmad, S., Jeske, W. P., Walenga, J. M., Hoppensteadt, D. A., Wood, J. J., Herbert, J.-M., Messmore, H. L., Fareed, J. (1999). Synthetic Pentasaccharides Do Not Cause Platelet Activation by Antiheparin-Platelet Factor 4 Antibodies. CLIN APPL THROMB HEMOST 5: 259-266 [Abstract]  
• Bick, R. L., Frenkel, E. P. (1999). Clinical Aspects of Heparin-Induced Thrombocytopenia and Thrombosis and Other Side Effects of Heparin Therapy. CLIN APPL THROMB HEMOST 5: S7-S15 [Abstract]  
• Walenga, J. M., Michal, K., Hoppensteadt, D., Wood, J. J., Robinson, J. A., Bick, R. L. (1999). Vascular Damage Correlates Between Heparin-Induced Thrombocytopenia and the Antiphospholipid Syndrome. CLIN APPL THROMB HEMOST 5: S76-S84 [Abstract]  
• Bacsi, S., De Palma, R., Visentin, G.P., Gorski, J., Aster, R.H. (1999). Complexes of Heparin and Platelet Factor 4 Specifically Stimulate T Cells From Patients With Heparin-Induced Thrombocytopenia/Thrombosis. Blood 94: 208-215 [Abstract] [Full Text]  
• Greinacher, A., Volpel, H., Janssens, U., Hach-Wunderle, V., Kemkes-Matthes, B., Eichler, P., Mueller-Velten, H. G., Potzsch, B. (1999). Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia : A Prospective Study. Circulation 99: 73-80 [Abstract] [Full Text]  
• Tien, Y., Yang, C., Ng, K., Wu, M., Lai, P., Huang, C. (1999). Thrombosis of the inferior vena cava in a pregnant woman with nephrotic syndrome - diagnostic and therapeutic dilemma. Nephrol Dial Transplant 14: 210-213 [Abstract]  
• Dupont, E. L., Gahtan, V., Mills, J. L. (1999). Heparin-Induced Thrombocytopenia: An Jatrogenic Catastrophe. VASC ENDOVASCULAR SURG 33: 43-49 [Abstract]  
• Berkowitz, S. D., Harrington, R. A., Rund, M. M., Tcheng, J. E. (1997). Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy. Circulation 95: 809-813 [Abstract] [Full Text]  
• Schwarz, R. P. JR, Becker, J.-C. P., Brooks, R. L., Hursting, M. J., Joffrion, J. L., Knappenberger, G. D., Kogan, T. P., Kogan, P. W., McKinney, A. A. (1997). State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor. CLIN APPL THROMB HEMOST 3: 1-15 [Abstract]  
• Owings, J. T., Blaisdell, F. W. (1996). Low-Dose Heparin Thromboembolism Prophylaxis. Arch Surg 131: 1069-1073 [Abstract]